Kornimate/medical-research-clean huggingface dataset:
efficacy of whole extract of licorice in neurological improvement of patients after acute ischemic stroke

Conditions: Acute Stroke

Summary: stroke is one of the most important causes of mortality and disability both in developed and developing countries. the only food and drug administration (fda) approved therapy for acute stroke is recombinant tissue plasminogen activator (rtpa). but narrow therapeutic window has limited the usefulness of thrombolytic therapy. therefore, finding effective neuroprotective drugs for the patients for whom thrombolysis is contraindicated or not feasible seemed to be mandatory in the world of cerebrovascular medicine. licorice, extracted from root of a plant scientifically known as glycyrrhiza glabra, is used in food industries. certain medical properties has been contributed to licorice and specifically to its active chemical components such as flavonoids and glycyrrhizic acid (ga). ga has been revealed to assert its anti-inflammatory effect by suppression of nf-κb, a key component of lipopolysaccharide-induced inflammatory response. neuroprotective characteristics of ga has been widely investigated in recent studies. in the present study, the investigators verified the efficacy and safety of oral administration of two different doses licorice extract in the patients with acute ischemic stroke, in a double-blind randomized controlled trial.


Eligibility criteria:
inclusion criteria: * symptoms of acute ischemic stroke * rosier score higher than 2 * confirmation of ischemic brain damage in ct scan exclusion criteria: * clinically relevant preexisting neurological deficit or previous cva * primary intracerebral hemorrhage * coma (level of consciousness more than 2 in nihss scale). * negative swallow test * patients undergoing hemicraniectomy * history of epilepsy * clinical seizure at onset of stroke * systolic bp is \>160 mmhg, diastolic bp\>110 at onset of stroke (if a rise in blood pressure occurred in the course of study it was controlled according to medical guidelines) * atrial fibrillation or other tachy/bradyarrythmias at time of allocation or in the middle of intervention * ejection fraction less than 45% * potassium less than 4 meq/dl at onset of stroke * malignancy or premalignant state within 5 years * myocardial infarction in previous month * significant kidney disease (creatinine higher than 1.8 mg/dl) * significant liver disease (bilirubin \> 20 mmoll/l) * significant lung disease (fev1 \ 45) * psychiatric illness requiring hospital admission * warfarin intake * digoxin intake * pregnancy * breast feeding * inability to have follow/up

Keywords: licorice glycyrrhizic acid ischemic stroke acute
mitochondrial function in peripheral arterial disease

Conditions: Peripheral Arterial Disease; Cardiovascular Diseases

Summary: the aim of this study is to investigate the effect of different treatment strategies on mitochondrial function and to correlate in-vitro results to findings from in-vivo measurements of mitochondrial function. the authors hypothesize that interventional revascularization and therefore the restoration of blood and oxygen supply is more relevant to mitochondrial function compared to the effect of exercise training.

resulting from a chronic narrowing of arteries by atherosclerotic lesions, the leading clinical symptom of peripheral arterial disease (pad), a walking induced pain, reduces quality of life of patients. affected muscle regions are altered by a characterized myopathy and mitochondria are known to play a crucial role in this pathophysiological mechanism. there are different methodological approaches to investigate mitochondrial function in-vivo as well as in-vitro. regarding our own preliminary data, mitochondria are known to recover after successful revascularization. the effect of different treatment strategies on mitochondrial function and the correlation of in-vitro to clinical more applicable in-vivo methods was understudied so far. the overall aim of this study is to investigate the effect of different treatment strategies on mitochondrial function and to correlate in-vitro results to findings from in-vivo measurements of mitochondrial function. the authors hypothesize that interventional revascularization and therefore the restoration of blood and oxygen supply is more relevant to mitochondrial function compared to the effect of exercise training. patients with isolated pathologies of the superficial femoral artery and symptomatic pad (fontaine stage iib) will be included and randomized to different treatment groups (conservative treatment versus interventional revascularization). near-infrared refracted spectroscopy and the tivita ® hyperspectral camera will be used for in-vivo measurement of peripheral oxygen saturation and distal perfusion before and after an exercise. muscle biopsies will be obtained from affected (gastrocnemius muscle) as well as from unaffected muscle (lateral vastus muscle) shortly before and 12 weeks after initiating treatment. muscle samples will be investigated by measurement of csa regarding mitochondrial content and hrr regarding mitochondrial respiration as well as for oxidative stress.

Eligibility criteria:
inclusion criteria: * isolated flow limiting arteriosclerotic lesion of the superficial femoral artery * unilateral grade ii b (fontaine) peripheral arterial disease * informed consent exclusion criteria: * flow limiting arteriosclerotic lesions of the infrarenal aorta, iliac arteries or common/ deep femoral artery * contraindication for exercise therapy

Keywords: mitochondrial function respirometry near infrared spectroscopy endothelial dysfunction peripheral arterial disease exercise training revascularisation
pd-l1 and other immuno-markers influenced by osimertinib treatment in advanced nsclc patients

Conditions: Small Cell Lung Cancer, Polygonal Type

Summary: the study will investigate whether pd-l1 and other immuno-markers will be influenced by osimertinib treatment in advanced epidermal growth factor receptor （egfr）t790m positive advanced nsclc patients. in addition, we will explore whether pd-l1 and other immuno-markers can predict the safety and efficacy of subsequent use of immune checkpoint inhibitors at the time of pd due to osimertinib resistance.

investigate whether pd-l1 and other immuno-markers will be influenced by osimertinib treatment in advanced egfr t790m positive advanced nsclc patients. explore whether pd-l1 and other immuno-markers can predict the safety and efficacy of subsequent use of immune checkpoint inhibitors at the time of pd due to osimertinib resistance.

Eligibility criteria:
inclusion criteria: 1. the patient enrolled in astris or patient who are eligible for the astris study. 2. the patient is willing to provide informed consent form to provide specimen before osimertinib treatment and at the time of pd. 3. patients must be able to undergo a fresh tumor biopsy during screening or to provide an available tumor sample taken \<2 months prior to screening. 4. fine needle aspirate specimens are not acceptable. 5. specimens from metastatic bone lesions are typically unacceptable unless there is confirmed soft tissue component. 6. the tumor specimen submitted to establish eligibility should be of sufficient quantity to allow for pd-l1 ihc and other biomarker analyses (if applicable) and is preferred in formalin-fixed paraffin embedded blocks. exclusion criteria: 1. the patient does not have sufficient tumor tissue specimen available for detection. 2. the patient who is unwilling to use the existing data from medical practice for scientific research. 3. the patient who received immunotherapy therapy before.
human umbilical-cord-derived mesenchymal stem cell therapy in paraquat poisoning induced lung injury

Conditions: Paraquat Poisoning; Lung Injury

Summary: phase i-ii clinical trial-safety and efficacy of umbilical-cord-derived mesenchymal stem cell (uc-msc) in patients with paraquat poisoning induced lung injury, randomized,single blind, controlled prospective study.

phase i-ii clinical trial-safety and efficacy of umbilical-cord-derived mesenchymal stem cell (uc-msc) in patients with paraquat poisoning induced lung injury,randomized, single blind, controlled prospective study. forty patients will be selected and randomized into two groups: the first group of 20 patients will receive three-time injection of uc-msc and the remaining 20 patients will comprise the control group. every patient will maintain their standard treatment of paraquat poisoning, with maximum tolerated dosage without side effects. the day of last infusion will be considered day zero. from that moment, followup will be divided into 2 d,7 d,14 d, 28 d and 2 m. clinical results will be analyzed after completion of 2 months of followup.

Eligibility criteria:
inclusion criteria: * age between 15 and 60 y(including 15y) * a history of ingestion paraquat, and hospitalization within 96 hours after paraquat poisoning * no previous organic disease history of serious heart, liver, kidney and lung, etc; * patients with moderate poisoning (oral dose of 20-40mg of pq ion/kg of body weight) * patient or his legal agent signed informed consent voluntarily * capable of good communication with researchers and follow the entire test requirements exclusion criteria: * refused to sign informed consent * elderly high-risk patients * socially and mentally disabilities * hepatitis b, hepatitis c, hiv and tuberculosis patients * pregnant or perinatal women * severe organ failure patients * patients participated in clinical trials of other drugs within 3 months * other circumstances not suitable to the trial(mixed toxicants poisoning)

Keywords: paraquat poisoning lung injury stem cell therapy human umbilical cord mesenchymal stem cell phase 1/2 clinical study allogeneic stem cell transplantation
influence of presurgical orthodontic molding on the growth of newborns with unilateral cleft lip palate

Conditions: Cleft Lip and Palate; Unilateral Cleft Lip

Summary: orofacial clefts are the second most common birth deformity and vary in etiology and phenotype, e.g. isolated cleft palate, cleft lip or cleft lip palate. especially newborns with unilateral complete cleft lip and palate (uclp) present severe facial asymmetries auch as a broad and flat ala of the nose, a deviation of the columella and the philtrum to the non cleft side. since postnatal asymmetries can even remain after surgical lip closure in a alleviated shape, therapeutic presurgical orthodontic approaches to improve symmetrie of the nose and to achieve ideal conditions for lip surgery are essential. presurgical orthodontic treatment for newborns with uclp start within the first days after birth to separate oral and nasal cavitiy, to improve breathing and feeding and to regulate growth of the maxillary segments using passive appliances (passive alveolar molding (pam)). an advanced and widely spread concept is the nasoalveolar molding (nam) by grayson, which was first introduced in 1993 as a palate plate combined with a nasal stent as a non-invasive presurgical appliance to stimulate growth of the nose and use the postnatal potential to modulate the nasal cartilage. the aim of the nam therapy is to reduce nasal width, to reduce deviation of the columella to the non cleft side and to increase nostril height. however, due to inhomogeneous study designs and results, so far only a slightly positive effect using nam therapy could be detected and prospective, randomized clinical trials are necessary. the aim of the study is to analyse and to compare the effects of pam versus nam treatment in newborns with uclp in the first year of life. the following parameters will be analysed on defined study time points: nostril width, nasal morphology, cleft width, maxillary growth, statical and dynamical facial asymmetries and facial perception.


Eligibility criteria:
inclusion criteria: * newborns/infants with non-syndromal (ns) unilateral cleft lip palate (uclp) * signed informed consent by the parents or legal guardian exclusion criteria: * newborns/infants with syndromal (s) unilateral cleft lip palate (uclp) * insufficient adherence and compliance by the parents or legal guardian * withdrawal of informed consent by the parents or legal guardian

Keywords: passie alveolar molding nasoalveolar molding maxillary growth facial asymmetry
dose optimization for stroke evaluation

Conditions: Stroke; Cerebrovascular Disorders; Brain Ischemia; Infarction

Summary: this study is about rehabilitation of arm function after a stroke. the investigators are testing the dosage of therapy that is needed for meaningful recovery of arm and hand function. dosage of therapy refers to the amount of time (in this case, the total number of hours) that a person participates in treatment. the investigators hope to learn how much therapy time is needed in order for change to occur in arm and hand function after a person has had a stroke. eligible candidates must have had a stroke affecting the use of an arm or hand at least 6 months ago.


Eligibility criteria:
inclusion criteria: * ischemic or hemorrhagic stroke that occured at least 6 months ago. * at least 21 years of age * persistent arm and hand weakness, with some ability to release a grasp * able to provide consent to participate * no history of a medical condition that limited arm or hand use prior to the stroke * medically stable * able to participate for 10 months and attend evaluations at the university of southern california (usc) health sciences campus. * able to communicate in english or spanish. exclusion criteria: * severe upper extremity sensory impairment * neglect * current major depressive disorder * severe arthritis or orthopedic problems that limit arm or hand movement * pain that interferes with daily activities * currently enrolled in other rehabilitation or drug intervention studies * living too far from the training site to participate reliably * receiving oral or injected anti-spasticity medications during study treatment. * pregnancy.

Keywords: stroke hemiparesis physical therapy occupational therapy neurorehabilitation patient focused motor learning motor control skill acquisition skill training motor recovery task oriented training task specific training arm function hand function upper extremity arm therapy physical rehabilitation arm rehabilitation motor function
phase ii study of ipilimumab monotherapy in recurrent platinum-sensitive ovarian cancer

Conditions: Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line

Summary: to assess the incidence of drug-related adverse events of grade 3 or higher and the overall response associated with ipilimumab treatment

condition: ovarian cancer, second line, third line, or fourth line

Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com. key inclusion criteria * ovarian cancer that is not refractory or resistant to platinum-based therapy (refactory=progression while receiving any previous platinum regimen; resistant=progression within 6 months of any previous platinum regimen) * recipients of platinum/taxane-based chemotherapy as frontline regimen for ovarian cancer * an eastern cooperative oncology group performance status ≤1 * up to 4 prior lines of therapy for ovarian cancer * two groups are eligible: group 1. women who have not met the criteria for progressive disease following their most recent chemotherapeutic regimen were required to have: * demonstrated partial response or stable disease following the most recent chemotherapy regimen * evaluable or measurable disease, detected by baseline computed tomography (ct) or magnetic resonance imaging (mri) scan * received the last dose of their most recent chemotherapeutic regimen for ovarian cancer within 4 to 12 weeks of the first administration of ipilimumab group 2: women with disease progression while receiving or following the last dose of the most recent chemotherapeutic regimen were required to have: * measurable disease on a ct or mri scan performed within 28 days of first dose of ipilimumab. * received the last dose of their most recent chemotherapeutic regimen for ovarian cancer at least 4 weeks prior to the first administration of ipilimumab. key exclusion criteria * histologic diagnosis of borderline, low malignant potential epithelial carcinoma * for group 1, women with complete response on the most recent ovarian carcinomatherapy * presence of known brain metastases * second malignancy active within the past 5 years, with the exception of locally curable cancers that have no need for subsequent therapy * documented history of severe autoimmune or immune-mediated symptomatic disease requiring prolonged systemic immunosuppressive treatment * history of motor neuropathy considered to be of autoimmune origin or the of grade 2 or higher peripheral neuropathy * history of toxic epidermal necrolysis * prior therapies with immunosuppressive agents within the last 2 years (excluding low-dose corticosteroids) and prior therapies with cytotoxic drugs within 4 weeks * chronic use of systemic immunosuppressive drugs, ongoing use of immunotherapy or biologic therapy for the treatment of cancer, or prior use of ipilimumab or any immune-stimulating agent.
neoadjuvant chemotherapy with seeox regimen for borrmann type 4 gastric cancer

Conditions: Stomach Neoplasms; Gastric Cancer

Summary: scirrhous gastric cancer, also known as linitis plastic or borrmann type 4, is an aggressive tumor with an extremely poor prognosis. aggressive surgical procedures and adjuvant chemotherapies have not improved the survival rate. the purpose of this study is to determine whether neoadjuvant chemotherapy with seeox regimen via intra-arterial and intravenous administration are effective in the treatment of borrmann type 4 gastric cancer.

gastric cancer patients who diagnosed as borrmann type 4 would be included in this study.they would receive 3 cycles of neoadjuvant chemotherapy with seeox regimen via combined intra-arterial and intravenous administration. the treatment schedule consisted of 3 courses (each, 2-week administration and 1-week withdrawal) of intra-arterial administration of oxaliplatin (150mg), etoposide (100mg) and epirubicin(30mg) by seldinger method on day 1 and oral s-1(120mg) on days 1-14, followed by radical surgery.the efficacy and toxicity of seeox regimen would be examined.

Eligibility criteria:
inclusion criteria: * histologically confirmed gastric adenocarcinoma; * males or females, aged 30-70 years; * gastroscopy and abdominal computed tomography (ct) scan-confirmed typical scirrhous gastric cancer (without definitive ulceration) that invaded more than half of the stomach; * no peritoneal metastasis confirmed by laparoscopic exploration and with cytological examination of peritoneal washing of the douglas pouch; * eastern cooperative oncology group performance status of 0 or 1; * no serious concomitant diseases that make survival period \< 3 years; * no prior anti-tumor therapy; * have signed informed consent before the beginning of treatment. exclusion criteria: * patients can not bear surgical procedure; * pregnant or lactating women; * previous cytotoxic chemotherapy, radiotherapy or immunotherapy; * with peritoneal metastasis or distant metastasis; * history of another malignancy within the last five years; * history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake; * clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery disease, new york heart association (nyha) grade ii or greater congestive heart failure or serious cardiac arrhythmia requiring medication or myocardial infarction within the last 12 months; * organ allografts requiring immunosuppressive therapy; * serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease; * moderate or severe renal impairment: serum creatinine \> 1.5 x upper limit of normal (uln); * hypersensitivity to any drug of the study regimen; * unwilling or unable to comply with the protocol for the duration of the study.

Keywords: gastric cancer borrmann type 4 neoadjuvant chemotherapy intra-arterial administration
development and validation of a symptom scale for children with chronic graft-versus-host disease

Conditions: Graft vs Host Disease

Summary: chronic graft-versus-host disease (cgvhd) is an important cause of morbidity and mortality in patients undergoing allogeneic bone marrow transplantation. cgvhd usually occurs after 100 days following transplantation and develops in 20-60% of transplant recipients. the incidence of cgvhd varies depending on the age of the marrow recipient, the use of sibling or unrelated donor bone marrow, the use of unmanipulated t cell-depleted bone marrow, and perhaps other factors. clinically, cgvhd is characterized by multi-system disease, which frequently mimics the clinical features of autoimmune diseases. the manifestations include skin changes (lichenoid and sclerodermatous changes, changes in pigmentation, loss of accessory structures such as hair, dystrophic nails, and rash), joint contractures, severe cramping, hepatic dysfunctions, sicca syndrome, obstructive lung disease, esophageal dysmotility, weight loss, polyserositis, immunodeficiency, and autoantibodies including anti-nuclear antibody, anti-erythrocyte antibodies, and anti-platelet antibodies.

a large number of children with cgvhd have to deal with many years of a disfiguring and painful chronic illness with the side effects of long term steroid use. the number of stem cell transplants done in children is only growing given that we are now transplanting patients with a variety of nonmalignant disorders and given the use of alternative donor sources. the broad categories of limited and extensive cgvhd are recognized by clinicians, but are not particularly useful in clinical practice. since cgvhd may involve almost every organ system adn since cgvhd constitutes a waxing and waning nature, cgvhd makes clinical management very difficult and complicated. currently, there is a symptoms scale used in the adult population for measuring symptom burden for adults with cgvhd. this scale is called the "lee symptoms scale". the purpose of this project is to develop a scale that is similar in design to the lee scale, but it is specifically designed to measure the burden of cgvhd in the pediatric population

Eligibility criteria:
inclusion criteria: * 5-18 years of age * prior allogeneic stem cell transplant, with any graft source, donor type, and gvhd prophylaxis allowed * clinical diagnosis of cgvhd * need for systemic treatment, defined as any medication or intervention delivered * no evidence of primary disease relapse * signed, informed consent, and if applicable, adolescent assent exclusion criteria: * inability to give signed informed consent

Keywords: cgvhd